NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis $47.25 +0.43 (+0.92%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$47.25 0.00 (0.00%) As of 10/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rigel Pharmaceuticals Stock (NASDAQ:RIGL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rigel Pharmaceuticals alerts:Sign Up Key Stats Today's Range$47.01▼$48.5250-Day Range$40.17▼$49.4252-Week Range$24.95▼$52.24Volume167,849 shsAverage Volume241,441 shsMarket Capitalization$874.13 millionP/E Ratio2.90Dividend YieldN/APrice Target$59.00Consensus RatingModerate Buy Company Overview Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes small-molecule medicines for immune and hematologic diseases. Founded in 1996 and headquartered in South San Francisco, California, the company focuses on therapies designed to address significant unmet medical needs in areas including autoimmune disorders, inflammatory conditions and cancer. Rigel’s marketed products include TAVALISSE (fostamatinib), an oral spleen tyrosine kinase inhibitor approved in the United States to treat adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment. The company also markets REZLIDHIA (olutasidenib), an oral targeted therapy approved for adults with relapsed or refractory acute myeloid leukemia whose cancer cells have a susceptible IDH1 mutation. The company commercializes its products in the United States and works with regional or international partners to support availability in other markets. Rigel also maintains a research and development pipeline focused on targeted therapies for immune-mediated diseases and hematologic cancers. Raul Rodriguez has served as the company’s president and chief executive officer, providing leadership as Rigel has expanded from a research-focused biotechnology company into a commercial-stage pharmaceutical business.AI Generated. May Contain Errors. Read More Rigel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreRIGL MarketRank™: 4.54073587385 of 5 starsRigel Pharmaceuticals scored higher than 91% of companies evaluated by MarketBeat, and ranked 32nd out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingRigel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialRigel Pharmaceuticals has a consensus price target of $59.00, representing about 24.9% upside from its current price of $47.25.Amount of Analyst CoverageRigel Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rigel Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth44.97% Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow by 44.97% in the coming year, from $2.98 to $4.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is 2.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 36.32.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is 2.90, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 212.19.Price to Book Value per Share RatioRigel Pharmaceuticals has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rigel Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.24% of the float of Rigel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 11.14, which indicates bearish sentiment.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently decreased by 10.54%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.04 News SentimentRigel Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Rigel Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest5 people have searched for RIGL on MarketBeat in the last 30 days. MarketBeat Follows10 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.47% of the stock of Rigel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rigel Pharmaceuticals' insider trading history. Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RIGL Stock News HeadlinesRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)October 2, 2026 | prnewswire.comRIGL.OQ - | Stock Price & Latest News | ReutersOctober 1, 2026 | reuters.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - SlideshowSeptember 15, 2026 | seekingalpha.comRigel Pharmaceuticals op H.C. Wainwright-conferentie: groeiplan verbreedSeptember 15, 2026 | nl.investing.comRigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - SlideshowSeptember 15, 2026 | seekingalpha.comRigel to Participate in Upcoming September Investor ConferencesSeptember 2, 2026 | prnewswire.comRigel PharmaceuticalsAugust 17, 2026 | money.usnews.comSee More Headlines RIGL Stock Analysis - Frequently Asked Questions How have RIGL shares performed this year? Rigel Pharmaceuticals' stock was trading at $42.83 at the beginning of the year. Since then, RIGL shares have increased by 10.3% and is now trading at $47.25. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported $0.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.79. The biotechnology company earned $78.70 million during the quarter, compared to the consensus estimate of $55.28 million. Rigel Pharmaceuticals had a net margin of 116.30% and a trailing twelve-month return on equity of 22.95%. Read the conference call transcript. When did Rigel Pharmaceuticals' stock split? Rigel Pharmaceuticals shares reverse split on Thursday, June 27th 2024.The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Rigel Pharmaceuticals' major shareholders? Rigel Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (2.90%), Venture Visionary Partners LLC (0.03%), State of Alaska Department of Revenue (0.03%) and Juncture Wealth Strategies LLC (0.02%). Insiders that own company stock include Raul R Rodriguez, Dean L Schorno, David A Santos, Walter H Moos and Kamil Ali-Jackson. View institutional ownership trends. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Novavax (NVAX), Plug Power (PLUG), NIO (NIO) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/04/2026Today10/16/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RIGL's financial health is in the Green zone, according to TradeSmith. RIGL has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RIGL CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees174Year Founded1996Price Target and Rating Average Price Target for Rigel Pharmaceuticals$59.00 High Price Target$85.00 Low Price Target$38.00 Potential Upside/Downside+24.9%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$16.32 Trailing P/E Ratio2.90 Forward P/E Ratio15.86 P/E GrowthN/ANet Income$367.02 million Net Margins116.30% Pretax Margin30.92% Return on Equity22.95% Return on Assets17.19% Debt Debt-to-Equity RatioN/A Current Ratio1.94 Quick Ratio1.79 Sales & Book Value Annual Sales$294.28 million Price / Sales2.97 Cash Flow$6.81 per share Price / Cash Flow6.94 Book Value$21.57 per share Price / Book2.19Miscellaneous Outstanding Shares18,500,000Free Float16,565,000Market Cap$874.13 million OptionableOptionable Beta1.19 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:RIGL) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RIGL Stock Alerts